Edition:
United States

Recipharm AB (publ) (RECIb.ST)

RECIb.ST on Stockholm Stock Exchange

90.00SEK
18 Dec 2017
Change (% chg)

0.75kr (+0.84%)
Prev Close
89.25kr
Open
89.75kr
Day's High
90.50kr
Day's Low
89.50kr
Volume
55,774
Avg. Vol
158,343
52-wk High
131.00kr
52-wk Low
84.00kr

Summary

Name Age Since Current Position

Lars Backsell

65 2007 Chairman of the Board

Thomas Eldered

57 2008 Chief Executive Officer, Director

Henrik Stenqvist

50 2017 Chief Financial Officer, Executive Vice President

Carl-Johan Spak

61 Executive Vice President, Global Technologies

Jean-Francois Hilaire

53 2015 Executive Vice President, Strategy and Global Integration

Mark Quick

51 Executive Vice President, Corporate Development

Thomas Beck

48 Senior Vice President, Quality Management

Jonas Lejontand

39 Vice President, Human Resources

Kenth Berg

58 Vice President Business Management

Erik Haeffler

50 Vice President, Manufacturing Services; Head of CSR

Kjell Johansson

61 President, Manufacturing Services Europe

Anders Carlberg

74 1995 Independent Director

Olle Christenson

61 1995 Independent Director, Employee Representative

Marianne Dicander Alexandersson

58 2014 Independent Director

Helena Levander

60 2016 Independent Director

Wenche Rolfsen

65 2016 Independent Director

Tony Sandell

74 1995 Independent Director

Carlos von Bonhorst

60 2015 Independent Director

Biographies

Name Description

Lars Backsell

Mr. Lars Backsell has served as Chairman of the Board of Directors of Recipharm AB since 2007. He has been Member of the Company’s Board since 1994. He serves as Chairman of the Company’s Remuneration Committee and Member of the Company’s Audit Committee. He holds a Bachelor of Science degree in Economics and Business Administration from Handelshogskolan i Stockholm (1978) and studied at AMP Insead, France (1989). He previously was Chief Executive Officer of Recip AB, 1995–2007 and Coloplast AB, 1981-1985; Business Area Manager OTC, Pharmacia AB, 1991–1994; Sales Director, Coloplast A/S Denmark, 1986–1991 and Controller at Hovas Invest AB (1978-1980). He serves as Chairman of the Board of Backsell Eldered Holding AB and board member of B&E Participation AB, B&E Invest AB, Rohirrim AB, Cajelo AB and Cajelo Invest AB, as well as Deputy Director of Recipharm fastigheter AB and Fellow of the Royal Academy og Engineering Science (IVA) and Chairman of the Board of Entreprenorskapsforum. He was Chairman of the Board of IVAs Naringslivsrad, Board Member of Aros Growth Capital AB, Lund University BioScience AB, PROBI Aktiebolag, BioInvent international AB and Skarmare Drifts AB as well as held board positions within the Group.

Thomas Eldered

Mr. Thomas Eldered has served as Chief Executive Officer of Recipharm AB since 2008, and has been Member of the Company’s Board of Directors since 1994. He holds a Master of Science degree in Industrial and Management Engineering from Linkoping Institute of Technology (part of Linkopings Universitet, 1985). He previously was Vice President at Recip AB 1995–2007; and factory manager at Pharmacia 1990–1995. He also serves as Chairman of the Board of Cobra Biologics Holding AB, B&E Participation Inc, Chromafora AB, Flerie Invest AB, Flerie Participation AB, Kahr Medical Ltd, Provell Pharmaceutical LLC, deputy board member of Symcel Sverige AB and Empros Pharma AB. In addition, he has held several different assignments as Chairman of the Board and board member of companies in the Group. He previously was Chairman of the Board of Empros Pharma AB and Board Member of Backsell Eldered Holding AB, B&E participation AB, among others.

Henrik Stenqvist

Mr. Henrik Stenqvist has been appointed Chief Financial Officer and Executive Vice President at Recipharm AB (publ) effective as of April 24, 2017. He has 24 years’ finance and management experience. Prior to joining Recipharm he served as CFO of the Meda Group and held other leading finance positions in the pharmaceutical industry. He holds a degree in Finance and Business Administration from the University of Linkoping, Sweden.

Carl-Johan Spak

Mr. Carl-Johan Spak serves as Executive Vice President, Global Technologies at Recipharm AB. He has been employed by the Company since 2009, and was previously employed at the Company from 1995 until 2007. He is Dentist from Karolinska Institutet (1980) and holds a Doctorate of Philosophy degree from Karolinska Institutet (1984). He previously was Director Nordic Region, Country Manager Sweden at Meda AB, 2007–2008, CEO Recip AB and Recip Lakemedel AB, 2005–2007, and Member of the Senior Management at Recip AB, 1997-2005. He also serves as Member of the Board in Empros Pharma AB, Symcel Sweden AB, Xspray Microparticles AB, Pharmanest AB, Synthonics Inc, Prokarium Ltd and KAHR Medical Ltd. In addition, he is Member of the board of Cobra Biologics. Previously, he was CEO of Empros Pharma AB, Board Member of Cobra Biologics AB, CEO and Deputy Board Member of Recip AB.

Jean-Francois Hilaire

Mr. Jean-Francois Hilaire has served as Executive Vice President, Strategy and Global Integration of Recipharm AB since June 1, 2015. He is Doctor of Pharmacy from the university of Bordeaux and alumni of the CEDEP General Management Program (campus INSEAD – Fontainebleau). He was previously Director Manufacturing Network Optimization at Abbott, Executive Vice President at Solvay, GM Germany and Eastern Europe at Laboratoires Fournier.

Mark Quick

Mr. Mark Quick serves as Executive Vice President, Corporate Development at Recipharm AB. He has been employed by the Company since 2006. He holds a Bachelor of Science degree (with Honors) in Industrial Studies from Nottingham Trent University (1988) and a Master of Business Administration degree from Open University (2005). He previously served as Head of Business Development at Celltech Manufacturing Services (2000–2006).

Thomas Beck

Mr. Thomas Beck serves as Senior Vice President, Quality Management at Recipharm AB (publ). He has been employed at the Company since 2015. He holds M.Sc. in Chemical Engineering, Royal Institute of Technology, Accreditation as Qualified Person, Uppsala University. He has experience as Director QA/QC, Qualified Person Recipharm Stockholm 2010-2015, Associate Director QA AstraZeneca R&D 2006-2010, Director QA, AstraZeneca Sweden Operations 2004-2006, Positions in Engineering, Manufacturing and Development at Pharmacia and AstraZeneca 1996-2004. He is Vice Chairman of the Board of Swedish Pharmaceutical Society, department of Quality Assurance.

Jonas Lejontand

Mr. Jonas Lejontand serves as Vice President, Human Resources at Recipharm AB. He has been employed by the Company since 1999. He holds a Bachelor of Science degree in Human Resources Management from Uppsala Universitet (2004). He has experience from senior positions within the Group.

Kenth Berg

Mr. Kenth Berg serves as Vice President Business Management at Recipharm AB. He has been employed by the Company since 1997. He is Market Economist from Lunds Universitet (1989). He was previously Board Member of Recipharm Strangnas AB. He has experience from senior positions within the Company and senior marketing positions at Ivers-Lee and Inpac AB (1988-1997).

Erik Haeffler

Mr. Erik Haeffler serves as Vice President, Manufacturing Services and Head of CSR at Recipharm AB (publ). He has been employed at the Company since 2015. He holds B.A. in Communication Studies, Stockholm University 1992. He has experience as EVP Supply Chain & Manufacturing 2009-2014, Meda AB. He also held several senior positions at Astra and AstraZeneca within Supply Chain and Manufacturing (1992-2009).

Kjell Johansson

Mr. Kjell Johansson serves as President, Manufacturing Services Europe at Recipharm AB. He has been employed by the Company since 2011. He holds a Master of Science degree in Chemical Engineering from Lund Institute of Technology (part of Lunds Universitet, 1981), and a Bachelor of Science degree in Economics from Stockholm University (Stockholms universitet, 1987). He previously was Management Consultant (2008–2011), Vice President Global Supply Chain (2004–2008), and Vice President Manufacturing (1989–2004), at AstraZeneca. He has also served as Member of the Board in CCS Healthcare Holding AB and CCS Healthcare Nordic AB, and Owner and Chairman in Castanie AB. He was previously Chairman of the Board of Biotechvalley AB, Recipharm Hoganas AB and Recipharm Strangnas AB, as well as Board Member of CCS Healthcare AB and external CEO of Recipharm Stockholm AB.

Anders Carlberg

Mr. Anders G. Carlberg has served as Independent Member of the Board of Directors of Recipharm publ AB since 1995. He is also Chairman of the Company’s Audit Committee. He holds Master of Business Administration degree from Lunds Universitet (1968). Previously, he was President and Chief Executive Officer at Axel Johnson International AB, 1993–2008, and President and Chief Executive Officer at Nobel industries and JS Saba, as well as Vice President at SSAB. He also serves as Chairman of the board of Herenco Aktiebolag, Granges AB, AxFast AB, Beijer-Alma AB, SWECO AB (publ), Investmentaktiebolaget Latour, and Owner of the sole proprietorship Narlunda Sateri. He was previously Chairman of the Board of AxIndustries Aktiebolag and Hoganas Aktiebolag, as well as Board Member of Martin & Servera Aktiebolag, Emballator AB and SSAB, among others.

Olle Christenson

Mr. Olle Christenson has been Independent Director, Employee Representative at Recipharm AB (publ) since 1995. He was previously Deputy Board Member of Q Information Aktiebolag.

Marianne Dicander Alexandersson

Ms. Marianne Dicander Alexandersson has been Independent Director at Recipharm AB since March 10, 2014. She holds Master of Science in Chemical Engineering, Chalmers Institute of Technology, Goteborg, 1983. She has experience as Former Chief Executive Officer of GHP AB and the Sixth Swedish National Pension Fund (Sjatte AP-fonden), Vice Chief Executive Officer Apoteket AB, Chief Executive Officer Kronans Droghandel and experience from quality management and marketing from several industry sectors such as the automotive industry, the plastics and chemicals industry as well as medicine and health care logistics. She is Founder and Chairman of MDA Management AB, Chairman of Sahlgrenska Science Park, member of the representative assembly of Skandia, member of The Dental and Pharmaceutical Benefits Agency (TVL) insights council, Chairman of the Royal Swedish Academy of Engineering Sciences (IVA) west section as well as board member in Camurus AB, Addera Care and Enzymatica AB. She was previously Board member of Molnlycke Healthcare AB and other companies within Molnlycke Group, as well as Board member of Castellum AB, Chalmers University of Technology, Confederation of Swedish Enterprise (Svenskt Naringsliv) and Bariatric and Diabetes Center Ajman AB, as well as in Apoteksakademin.

Helena Levander

Ms. Helena Levander has been Independent Director of Recipharm AB (publ) since April 28, 2016. She holds M.Sc. (Econ), Stockholm School of Economics. She has background with SEB, as Senior Equity Fund Manager, Nordea Asset Management, CEO, Odin Fonder, founder and CEO, Neonet Securities AB, Founder and CEO of Nordic Investor Services AB. She is also Board member of Concordia Maritime AB, Stampen AB, Neurovive Pharmaceutical AB, Pensare Grande AB and Medivir AB and Chairman, Nordic Investor Services AB. She previously held directorships in companies in the Stampen Group, was Board member, Aktiebolaget Svensk Exportkredit, Collector AB, Collector Credit Bank AB, Erik Penser Aktiebolag, Rederi AB Transatlantic, Alba Holding AB, Betting Promotion Sweden AB, Wiborg Kapitalforvaltning, Erik Penser Bankaktiebolag, SBAB Bank AB (publ) and Uniflex AB. CEO, Nordic Investor Services AB.

Wenche Rolfsen

Ms. Wenche Rolfsen has been Independent Director of Recipharm AB (publ) since April 28, 2016. She holds Ph.D. from the Pharmaceutical Faculty, Uppsala University. She has been Adjunct Professor Pharmaceutical Faculty, Uppsala University since 2002. She also serves as Board member of Swedish Match AB, Moberg Pharma AB, Bioarctic AB and Board member and CEO, Rolfsen Consulting AB, as well as Chairman of Index Holding AB and Sarsia Seed. She was previously Chairman, Aprea AB, Denator AB and Aprea Personal AB, Board member, Swedish Orphan Biovitrum AB (publ), TFS Trial Form Support International AB, Artimplantant AB (bankruptcy initiated 01/08/2013), Jederstrom Pharmaceuticals AB (bankruptcy initiated 19/12/2011) and Apotek Produktion & Laboratorier AB, Board member and CEO, Quintiles AB. She also served as Head of Pharmacology at Pharmacia & Upjohn.

Tony Sandell

Mr. Tony Sandell has served as Independent Member of the Board of Directors of Recipharm AB since 1995. He is Member of the Company’s Audit Committee. He holds a LLB degree from Stockholms universitet (1969). He is Attorney. He is also Former member of the Board of the Swedish Bar Association, chairman of DFA, Delegationen for advokatforsakringar (Delegation for attorney insurance), board member for LES, Licensing Executives Society, member of IBA, International Bar Association. He serves as Chairman of the board of MFEX Mutual Funds Exchange AB, board member of Tony Sandell AB. He was previously Board Member of Danfo Holding Aktiebolag, publisher Natur och Kultur, Swedish Business Development Aktiebolag, Are 2007 AB and Eriks Brand Aktiebolag, auditor for Fjallbergsvind (co-operative association).

Carlos von Bonhorst

Mr. Carlos von Bonhorst has been Independent Director of Recipharm AB (publ) since May 7, 2015. He is Medical Doctor, Classical University, Lisbon, Portugal (1981). He has experience as Consultant to the board/top management of Portuguese (JABA, Lusomedicamenta, Santo, Tecnifar), Swiss (Helsinn), and Irish (Newport) companies. He has also been Consultant and research programs evaluator in the field of Biomedical and Health Sciences for Governments: Belgium Federal and Regional-Walloon, French-ANR, Italian Regional-Veneto; Consultant to International Institutions and NGOs- European Commission, Sweden Bio (Sweden), ARVO (US), EVS (Belgium) in respect to research funding; Expert for the European Commission for the past 20 years in the research fields of Life Sciences, Health, Nanotechnologies and Emerging Technologies; Owner of a technology transfer office; Former Business Development Director, Biofarma, Portugal, former Corporate Development Director, Helsinn, Switzerland. He is former Board Member of Pharmaceutical, Chemical and Investment companies in Ireland, Switzerland and Belgium.